Lenzetto

Estradiol, the active ingredient in Lenzetto, is a estrogen presented as a transdermal patch for transdermal use. It treats estrogen deficiency and related conditions in postmenopausal women, helping to relieve vasomotor symptoms and support bone health. GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto is an estrogen‑based therapy used to address conditions linked to low endogenous estrogen levels. - Menopausal vasomotor symptoms: reduces frequency and severity of hot flashes and night sweats. - Estrogen deficiency: restores hormonal balance and alleviates associated discomfort. - Prevention of osteoporosis: helps maintain bone mineral density and reduces fracture risk in postmenopausal women.

Adverse reactions may occur with any estrogen therapy.

Common Side Effects: - Skin irritation at the patch site: redness, itching, or rash. - Headache: mild to moderate intensity. - Breast tenderness: discomfort or swelling. - Nausea: occasional upset stomach. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke or myocardial infarction: increased cardiovascular risk. - Endometrial hyperplasia or carcinoma: abnormal uterine bleeding. - Hepatic dysfunction: jaundice or elevated liver enzymes. - Severe allergic reaction: anaphylaxis or angioedema.

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately. - Cardiovascular risk assessment: evaluate history of thrombosis, stroke, or myocardial infarction. - Breast cancer surveillance: conduct regular examinations and imaging as indicated. - Liver function monitoring: check hepatic enzymes periodically. - Use lowest effective dose: adjust based on symptom control and side‑effect profile. - Contraindicated in pregnancy: avoid use in women who are or may become pregnant. - Store at room temperature: keep in original pouch, protect from light and moisture.

Estradiol may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Combined estrogen‑progestin oral contraceptives: increased risk of venous thromboembolism. - Warfarin: potentiation of anticoagulant effect, leading to bleeding. - Tamoxifen: antagonistic action reducing therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol plasma levels. - CYP3A4 inducers (e.g., rifampin): may lower estradiol exposure. - Selective serotonin reuptake inhibitors: can exacerbate hot flashes.